Residency · Residency · Internal Medicine

Atrial Fibrillation: Rate vs. Rhythm Control

Pathophysiology

Mechanisms of AF

Atrial fibrillation arises from a combination of electrical and structural abnormalities. The multiple wavelet hypothesis describes numerous re-entrant circuits propagating simultaneously through atrial tissue. Many episodes are initiated by focal triggers -- rapidly firing foci located predominantly at the pulmonary vein ostia. Over time, structural remodeling of the atria (fibrosis, dilation, and inflammation) creates a substrate that perpetuates AF. Electrical remodeling follows a self-reinforcing pattern: AF shortens atrial refractory periods, which in turn makes AF easier to sustain -- the principle that "AF begets AF." Autonomic triggers play a role as well, with vagal tone contributing to nocturnal AF and sympathetic activation driving adrenergic AF.

Classification

AF is classified by duration and treatment decisions. Paroxysmal AF self-terminates within seven days. Persistent AF lasts longer than seven days or requires cardioversion. Long-standing persistent AF has been continuous for more than 12 months. Permanent AF reflects an accepted decision by patient and physician that no further rhythm control will be attempted. Valvular AF, associated with moderate-to-severe mitral stenosis or a mechanical heart valve, carries the important distinction that it requires warfarin rather than a DOAC.

Risk Factors and Associated Conditions

Hypertension is the most common modifiable risk factor. Obesity and obstructive sleep apnea contribute significantly. Alcohol use can trigger AF in the classic "holiday heart syndrome." Heart failure has a bidirectional relationship with AF -- each worsens the other. Valvular heart disease (particularly mitral stenosis and regurgitation), hyperthyroidism, and pulmonary disease (PE, COPD) are established associations. AF occurs in 30 to 50 percent of patients after cardiac surgery. Age remains the strongest non-modifiable risk factor.

Clinical Presentation

Patients may report palpitations, an irregular heartbeat sensation, dyspnea, exercise intolerance, fatigue, lightheadedness, or chest discomfort. Many patients are entirely asymptomatic, with AF detected incidentally. Acute presentations include rapid ventricular response with hemodynamic instability, heart failure exacerbation, and stroke or systemic embolism. The hallmark physical finding is an irregularly irregular pulse.

Diagnostic Workup

ECG and Monitoring

The 12-lead ECG shows absence of P waves, irregularly irregular RR intervals, and a fibrillatory baseline. For detecting paroxysmal AF, a Holter monitor (24-48 hours) or event recorder (2-4 weeks) can be used. Implantable loop recorders are valuable for cryptogenic stroke workup and detection of occult AF. Smartwatches and wearable ECG devices play an increasing role in AF detection, though findings require confirmation with a clinical ECG.

Laboratory Workup

TSH should be checked in every case of new AF to exclude hyperthyroidism. Additional labs include CBC, basic metabolic panel, liver function tests, and coagulation studies. Echocardiography assesses LV function, atrial size, valvular disease, and LV hypertrophy.

Risk Assessment

The CHA2DS2-VASc score guides anticoagulation decisions for stroke prevention:

Points are assigned for congestive heart failure (1), hypertension (1), age 75 or older (2), diabetes (1), prior stroke or TIA or thromboembolism (2), vascular disease (1), age 65-74 (1), and female sex (1). A score of 0 in men or 1 in women warrants no anticoagulation; a score of 1 in men or 2 in women merits consideration; and a score of 2 or more in men or 3 or more in women makes anticoagulation recommended. The HAS-BLED score assesses bleeding risk, but a high score should not lead to withholding anticoagulation -- rather, it should prompt addressing modifiable bleeding risk factors.

Management

Anticoagulation

Direct oral anticoagulants (DOACs) are preferred over warfarin for non-valvular AF.

Apixaban 5 mg twice daily (reduced to 2.5 mg twice daily if two of three criteria are met: age 80 or older, weight 60 kg or less, creatinine 1.5 or higher) was shown to be superior to warfarin in the ARISTOTLE trial, with less bleeding and lower mortality. Rivaroxaban 20 mg daily with the evening meal (15 mg if CrCl 15-50) was studied in the ROCKET AF trial. Dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in the RE-LY trial, with the 110 mg dose being non-inferior and associated with less bleeding. Edoxaban 60 mg daily (30 mg if CrCl 15-50, weight 60 kg or less, or with certain P-gp inhibitors) was evaluated in the ENGAGE AF-TIMI 48 trial.

Warfarin remains indicated for mechanical heart valves, moderate-to-severe mitral stenosis, and severe CKD (CrCl below 15-25), with a target INR of 2.0-3.0 and a time-in-therapeutic-range goal above 70 percent. Left atrial appendage occlusion with the WATCHMAN device is an alternative for patients who have contraindications to long-term anticoagulation, with the PROTECT AF and PREVAIL trials demonstrating non-inferiority to warfarin.

Rate Control

The RACE II trial demonstrated that lenient rate control (resting heart rate below 110 bpm) is non-inferior to strict control (below 80 bpm), though strict control may be considered for patients who remain symptomatic. Beta-blockers (metoprolol, atenolol, carvedilol) are first-line for most patients. Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are alternatives but should be avoided in HFrEF. Digoxin serves as add-on therapy and is useful in HFrEF, though it requires level monitoring (target 0.5-0.9 ng/mL) and should not be used as monotherapy. Amiodarone has rate-controlling properties but its toxicity profile limits its use for rate control alone. AV node ablation with permanent pacemaker placement ("ablate and pace") is a last resort for refractory rate control.

Rhythm Control

Cardioversion

Electrical cardioversion is preferred for hemodynamically unstable patients. When AF duration exceeds 48 hours or is unknown, either three weeks of therapeutic anticoagulation before cardioversion or a transesophageal echocardiogram to exclude left atrial thrombus is required. Anticoagulation must continue for at least four weeks after cardioversion because of atrial stunning. Pharmacologic cardioversion options include IV ibutilide, IV flecainide, or IV procainamide.

Antiarrhythmic Drugs

Flecainide and propafenone are used in patients without structural heart disease and can be prescribed as "pill-in-the-pocket" for infrequent paroxysmal AF. Amiodarone is the most effective antiarrhythmic drug and is appropriate in structural heart disease and HFrEF, though it carries significant long-term toxicity affecting the thyroid, lungs, liver, skin, eyes, and nervous system. Sotalol combines beta-blocker and class III antiarrhythmic properties but requires QTc monitoring and should be avoided in HFrEF. Dofetilide requires in-hospital initiation with QTc monitoring and careful renal dosing. Dronedarone is less toxic than amiodarone but less effective, and it is contraindicated in HFrEF and permanent AF because the PALLAS trial showed harm.

Catheter Ablation

Pulmonary vein isolation (PVI) is the cornerstone procedure. The CABANA trial showed no significant difference in the composite outcome versus drugs, though significant crossover occurred and per-protocol analysis favored ablation. The CASTLE-AF trial demonstrated that ablation reduced death and heart failure hospitalization in AF patients with HFrEF. The EAST-AFNET 4 trial -- a paradigm-shifting study -- showed that early rhythm control within one year of diagnosis reduced cardiovascular outcomes compared to rate control. The EARLY-AF trial found early ablation superior to antiarrhythmic drugs for maintaining sinus rhythm in paroxysmal AF. Ablation is increasingly considered first-line, particularly in symptomatic paroxysmal AF and AF with HFrEF. Complications, though uncommon, include pulmonary vein stenosis, cardiac tamponade, phrenic nerve injury, and the rare but fatal atrioesophageal fistula.

Upstream Therapy and Risk Factor Modification

Weight loss of 10 percent is associated with significant reduction in AF burden (LEGACY study). Treatment of obstructive sleep apnea with CPAP, alcohol reduction or cessation, moderate exercise (noting that excessive endurance exercise may paradoxically promote AF), blood pressure optimization, and diabetes control all contribute meaningfully to AF management.

Complications

Without anticoagulation, AF increases the risk of stroke and systemic thromboembolism fivefold. Tachycardia-mediated cardiomyopathy is reversible with rate or rhythm control. Heart failure exacerbation, reduced quality of life, and an association with cognitive decline and dementia (even with anticoagulation) are additional consequences.

<image> An illustration of the left atrium showing the four pulmonary veins entering the posterior wall, with focal trigger sites marked as electrical discharge points at the pulmonary vein ostia. Show ablation lesion sets as dotted circular lines around each pulmonary vein pair (pulmonary vein isolation). Include the left atrial appendage with a thrombus forming inside. Label: pulmonary veins, left atrial appendage, mitral valve annulus, ablation lesion sets. Use a semi-transparent atrial wall to show internal anatomy. </image>

<image> A decision algorithm flowchart for AF management. Start with "Atrial Fibrillation Diagnosed" leading to two parallel tracks: (1) Stroke risk assessment with CHA2DS2-VASc score leading to anticoagulation decisions (DOAC vs warfarin vs LAA occlusion), and (2) Rate vs Rhythm control decision based on symptoms, duration, LV function, and patient preference. The rhythm control arm branches into AAD selection (with/without structural heart disease) and catheter ablation. Include the EAST-AFNET 4 finding favoring early rhythm control. Clean flowchart with blue headers and white decision boxes. </image>

<image> A comparative bar chart illustration showing the efficacy and safety of the four DOACs versus warfarin based on landmark trials (RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF). Display stroke/systemic embolism rates and major bleeding rates for each agent. Include a table below with dosing, renal adjustments, and reversal agents (idarucizumab for dabigatran, andexanet alfa for apixaban/rivaroxaban, 4-factor PCC). Use a clean infographic style with color-coded bars. </image>

Clinical Pearls

The CHA2DS2-VASc score drives anticoagulation decisions regardless of AF pattern -- paroxysmal AF carries the same stroke risk as persistent AF. The EAST-AFNET 4 trial represents a paradigm shift: early rhythm control within one year of diagnosis improves cardiovascular outcomes, challenging the long-held assumption from the AFFIRM era that rate control is equivalent. Catheter ablation is increasingly regarded as first-line for symptomatic paroxysmal AF and should be strongly considered in AF with HFrEF (CASTLE-AF). TSH should always be checked in new AF because hyperthyroidism is a reversible cause. Flecainide and propafenone must be avoided in patients with structural heart disease or coronary artery disease because of proarrhythmic risk (CAST trial). Patients on amiodarone need toxicity screening every 6 to 12 months: thyroid function tests, liver function tests, pulmonary function tests, and eye examination, with an annual chest X-ray. "Pill-in-the-pocket" flecainide is an option for selected patients with infrequent paroxysmal AF and no structural heart disease. Lenient rate control (heart rate below 110) is acceptable for most patients and avoids overtreatment (RACE II). DOACs must not be used for valvular AF (mechanical valve or moderate-to-severe mitral stenosis) -- warfarin is required. Weight loss and risk factor modification remain the most underutilized and effective treatments for AF.

References

• January CT, et al. 2019 AHA/ACC/HRS Focused Update on AF. Circulation. 2019.
• Hindricks G, et al. 2020 ESC Guidelines for AF. Eur Heart J. 2021.
• EAST-AFNET 4 Trial: Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with AF. NEJM. 2020.
• CASTLE-AF: Marrouche NF, et al. Catheter Ablation for AF with Heart Failure. NEJM. 2018.
• CABANA Trial: Packer DL, et al. JAMA. 2019.
• AFFIRM Trial: Wyse DG, et al. NEJM. 2002.
• RACE II Trial: Van Gelder IC, et al. NEJM. 2010.
• ARISTOTLE Trial: Granger CB, et al. NEJM. 2011.
• RE-LY Trial: Connolly SJ, et al. NEJM. 2009.
• LEGACY Study: Pathak RK, et al. JACC. 2015.

Read this lecture as Markdown